alkermes depression drug facing fda panel, here's what to know
Published 5 years ago • 605 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:42
fda set to review new drugs aimed at fighting depression
-
12:46
just how bad is alkermes' fda depression drug setback?
-
24:22
why alkermes' depression drug stumbled, and how illumina plans to profit from m&a
-
5:05
what to know about the fda-approved postpartum depression drug l gma
-
5:48
alkermes ceo: fundamental facts of pricing pharma | mad money | cnbc
-
3:35
new treatment for als provides hope for maine families battling disease
-
40:28
2023 wmif | the disruptors: the next wave of promising psychiatry and neurology drugs
-
10:59
the brewing fda battle over als treatment
-
4:00
here's how drug rebates work
-
4:41
fda expected to make final decision on alzheimer's drug leqembi today
-
6:27
sage therapeutics ceo: treating postpartum depression | mad money | cnbc
-
5:42
alkermes ceo richard pops: healthy gains | mad money | cnbc
-
4:03
cms limiting coverage of alzheimer's drug not a 'fixed' policy, says fda's robert califf
-
6:29
alkermes ceo: impact in addiction | mad money | cnbc
-
6:42
alkermes ceo: battling addiction | mad money | cnbc
-
4:07
sage therapeutics ceo on why its moving to treat depression next
-
0:33
axsome’s depression drug receives fda approval
-
8:09
alkermes antidepressant rejected by fda | alks 5461
-
0:45
fda approves new drug to slow progress of als
-
7:44
some cancer drugs remain unproven 5 years after fda's accelerated approval, study finds
-
2:13
nightly business report: alkermes’ promising treatment
-
7:37
alkermes ceo: is the takeover talk real? | mad money | cnbc